Shanghai SIMR Biotech

Company snapshot

SIMR is an innovation-oriented biopharmaceutical company dedicated to the discovery and development of new drugs for pain, inflammation and central nervous system related diseases. Since its establishment in 2014, the company has established a research and development platform of more than 3,000 square meters, with comprehensive drug development capabilities such as compound screening, CMC researc

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Shanghai SIMR Biotech. Not investment advice.

• What is Shanghai SIMR Biotech?

  Shanghai Chest Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Esophageal Cancer, Esophageal Squamous Cell Carcinoma, NSCLC. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from pu

• Is Shanghai SIMR Biotech publicly traded?

  Shanghai SIMR Biotech appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Shanghai SIMR Biotech develop or market?

  We link 14 drug profile(s) where Shanghai SIMR Biotech is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/shanghai-chest-hospital#company-drugs.

• What are the latest developments for Shanghai SIMR Biotech?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Shanghai SIMR Biotech focus on?

  Shanghai SIMR Biotech focuses on Esophageal Cancer, Esophageal Squamous Cell Carcinoma, NSCLC based on our analysis of their pipeline programs and drug development activities.